Zai Lab Limited (NASDAQ:ZLAB) Shares Bought by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its stake in Zai Lab Limited (NASDAQ:ZLAB) by 188.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,505,866 shares of the company’s stock after purchasing an additional 984,041 shares during the quarter. Allianz Asset Management GmbH owned approximately 1.38% of Zai Lab worth $39,442,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Janus Henderson Group PLC boosted its holdings in Zai Lab by 34.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock worth $211,488,000 after buying an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Zai Lab by 18.4% in the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after acquiring an additional 1,312,115 shares during the last quarter. Bamco Inc. NY increased its position in shares of Zai Lab by 6.4% during the third quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock worth $46,023,000 after purchasing an additional 113,869 shares in the last quarter. Principal Financial Group Inc. acquired a new position in Zai Lab in the 4th quarter valued at $46,172,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Zai Lab by 26.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after purchasing an additional 125,532 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Zai Lab Price Performance

ZLAB opened at $33.78 on Monday. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of -12.19 and a beta of 1.02. The company’s 50 day simple moving average is $26.90 and its two-hundred day simple moving average is $25.33. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $36.60.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.

Insider Activity at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the company’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the sale, the insider now directly owns 33,834 shares in the company, valued at $889,157.52. This represents a 18.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.88% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.